Polomar Health Services, Inc. (PMHS)
| Market Cap | 3.05M -73.8% |
| Revenue (ttm) | 1.65M +3,214.6% |
| Net Income | -10.27M |
| EPS | -0.37 |
| Shares Out | 28.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,901 |
| Open | 0.1500 |
| Previous Close | n/a |
| Day's Range | 0.1089 - 0.1500 |
| 52-Week Range | 0.0650 - 0.7999 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About Polomar Health Services
Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabetes management; and compounded erectile dysfunction medications inhalable... [Read more]
Financial Performance
In 2025, Polomar Health Services's revenue was $648,231, an increase of 1001.98% compared to the previous year's $58,824. Losses were -$10.70 million, 697.8% more than in 2024.
Financial StatementsNews
Polomar Health Services Strengthens Board Leadership to Support Standalone Growth Strategy
Polomar Health Services (OTCQB: PMHS) names George Hornig Executive Chairman and George Caruolo Lead Independent Director, adding three board members.